Publicacións en colaboración con investigadores/as de Hospital de Galdakao - Usansolo (21)

2022

  1. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

2020

  1. Evaluation of the Integrated Tuberculosis Research Program Sponsored by the Spanish Society of Pulmonology and Thoracic Surgery: 11 Years on

    Archivos de Bronconeumologia, Vol. 56, Núm. 8, pp. 483-492

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

2016

  1. Spanish Compliance With Guidelines for Prescribing Four Drugs in the Intensive Phase of Standard Tuberculosis Treatment

    Archivos de Bronconeumologia, Vol. 52, Núm. 5, pp. 262-268

2014

  1. Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82

2013

  1. A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 31, Núm. SUPPL.75

  2. Evidence of association of the NLRP1 gene with giant cell arteritis

    Annals of the Rheumatic Diseases

  3. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1882-1886

2012

  1. Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population

    Clinical and Experimental Rheumatology, Vol. 30, Núm. SUPPL. 70

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279

2011

  1. A nonsynonymous functional variant of the ITGAM gene is not involved in biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 38, Núm. 12, pp. 2598-2601

2006

  1. Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 2, pp. 96-117

  2. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: A cross-sectional study

    Cardiovascular Diabetology, Vol. 5

2005

  1. GEAM/SPNS recommendations for managing metabolic and morphologic alterations in patients with HIV infection

    Nutrition and Metabolic Disorders in HIV Infection, Vol. 4, Núm. 2, pp. 617-698

  2. Recommendations from GESIDA/SEFH/PNS to improve adherence to antiviral treatment (2004)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 4, pp. 221-231

2004

  1. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral en el año 2004

    Farmacia Hospitalaria

2003

  1. Infective endocarditis due to Streptococcus bovis in a series of nonaddict patients: Clinical and morphological characteristics of 20 cases and review of the literature

    Canadian Journal of Cardiology, Vol. 19, Núm. 10, pp. 1139-1145

2002

  1. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases

    Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492

1999

  1. Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional

    Archivos de Bronconeumologia, Vol. 35, Núm. 9, pp. 446-454

1998

  1. Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience

    Respiratory Medicine, Vol. 92, Núm. 10, pp. 1181-1187